Literature DB >> 26052915

IV pentamidine for primary PJP prophylaxis in adults undergoing allogeneic hematopoietic progenitor cell transplant.

M J Lim1, A Stebbings1, S J Lim1, K Foor1, J-Z Hou1, R Farah1, A Raptis1, S Marks1, D Weber1, A Im1, K Dorritie1, A Sehgal1, M Agha1, S H Lim1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26052915     DOI： 10.1038/bmt.2015.131

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  8 in total

1.  Aerosolized pentamidine as pneumocystis prophylaxis after bone marrow transplantation is inferior to other regimens and is associated with decreased survival and an increased risk of other infections.

Authors:  M J Vasconcelles; M V Bernardo; C King; E A Weller; J H Antin
Journal:  Biol Blood Marrow Transplant       Date:  2000       Impact factor: 5.742

2.  High rates of Pneumocystis carinii pneumonia in allogeneic blood and marrow transplant recipients receiving dapsone prophylaxis.

Authors:  J P Souza; M Boeckh; T A Gooley; M E Flowers; S W Crawford
Journal:  Clin Infect Dis       Date:  1999-12       Impact factor: 9.079

3.  Intravenous pentamidine is safe and effective as primary pneumocystis pneumonia prophylaxis in children and adolescents undergoing hematopoietic stem cell transplantation.

Authors:  James M DeMasi; Jennifer A Cox; David Leonard; Andrew Y Koh; Victor M Aquino
Journal:  Pediatr Infect Dis J       Date:  2013-09       Impact factor: 2.129

4.  Aerosolized pentamidine prophylaxis for Pneumocystis carinii pneumonia after allogeneic marrow transplantation.

Authors:  T K Marras; K Sanders; J H Lipton; H A Messner; J Conly; C K Chan
Journal:  Transpl Infect Dis       Date:  2002-06       Impact factor: 2.228

5.  A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group.

Authors:  S A Bozzette; D M Finkelstein; S A Spector; P Frame; W G Powderly; W He; L Phillips; D Craven; C van der Horst; J Feinberg
Journal:  N Engl J Med       Date:  1995-03-16       Impact factor: 91.245

6.  Pneumocystis carinii pneumonitis following bone marrow transplantation.

Authors:  I Z Tuan; D Dennison; D J Weisdorf
Journal:  Bone Marrow Transplant       Date:  1992-09       Impact factor: 5.483

7.  The value of Pneumocystis carinii antibody and antigen detection for diagnosis of Pneumocystis carinii pneumonia after marrow transplantation.

Authors:  J D Meyers; L L Pifer; G E Sale; E D Thomas
Journal:  Am Rev Respir Dis       Date:  1979-12

8.  Intravenous pentamidine is effective as second line Pneumocystis pneumonia prophylaxis in pediatric oncology patients.

Authors:  Su Young Kim; Alix A Dabb; Donald J Glenn; Kristen M Snyder; Meredith K Chuk; David M Loeb
Journal:  Pediatr Blood Cancer       Date:  2008-04       Impact factor: 3.167
  8 in total
  2 in total

1.  IV pentamidine for Pneumocystis jiroveci pneumonia prophylaxis in pediatric allogeneic stem cell transplant patients.

Authors:  D A Curi; R E Duerst; C Badke; J Bell; S Chaudhury; M Kletzel; J Schneiderman; W T Tse; W J Muller; N Hijiya
Journal:  Bone Marrow Transplant       Date:  2016-05-23       Impact factor: 5.483

2.  Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematologic malignancies and solid tumors: 2020 updated guidelines of the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO/DGHO).

Authors:  Annika Y Classen; Larissa Henze; Marie von Lilienfeld-Toal; Georg Maschmeyer; Michael Sandherr; Luisa Durán Graeff; Nael Alakel; Maximilian Christopeit; Stefan W Krause; Karin Mayer; Silke Neumann; Oliver A Cornely; Olaf Penack; Florian Weißinger; Hans-Heinrich Wolf; Jörg Janne Vehreschild
Journal:  Ann Hematol       Date:  2021-04-13       Impact factor: 3.673
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.